^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cavatak (gebasaxturev)

    i
    Associations
    News

    Trials

    Company:
    Merck (MSD)
    Drug class:
    ICAM-1 antagonist, CD55 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) (NCT03408587)
    Phase 1b
    Viralytics
    Completed
    Last update posted :
    05/04/2023
    Initiation :
    01/29/2018
    Primary completion :
    05/22/2019
    Completion :
    05/22/2019
    PD-L1
    |
    Yervoy (ipilimumab) • Cavatak (gebasaxturev)
    Pembrolizumab + CVA21 in Advanced NSCLC (NCT02824965)
    Phase 1/2
    Olivia Newton-John Cancer Research Institute
    Active, not recruiting
    Last update posted :
    07/07/2021
    Initiation :
    08/09/2017
    Primary completion :
    07/01/2021
    Completion :
    10/01/2021
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression • EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Cavatak (gebasaxturev)
    A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) (NCT00438009)
    Phase 1
    Viralytics
    Completed
    Last update posted :
    07/01/2019
    Initiation :
    05/16/2007
    Primary completion :
    08/28/2009
    Completion :
    08/28/2009
    ICAM1
    |
    Cavatak (gebasaxturev)
    Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04) (NCT00636558)
    Phase 1
    Viralytics
    Completed
    Last update posted :
    07/01/2019
    Initiation :
    02/29/2008
    Primary completion :
    01/12/2012
    Completion :
    01/12/2012
    ICAM1
    |
    Cavatak (gebasaxturev)